SCHEMBL20675596

SCHEMBL20675596

Cc1ccc2cc(C(C)C)cc(Cl)c2n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.43
RAB9A P51151 1/20 0.43
CCR5 P51681 1/20 0.43
MAPT P10636 2/20 0.41
MDM2 Q00987 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NR4A2 P43354 3/20 0.36
KDM4E B2RXH2 2/20 0.35
HTT P42858 2/20 0.35
GAA P10253 1/20 0.35
METAP2 P50579 1/20 0.34
CYP1A2 P05177 2/20 0.33
POLB P06746 1/20 0.33
PDE2A O00408 1/20 0.33
PDE10A Q9Y233 1/20 0.33
PKM P14618 1/20 0.33
BDKRB2 P30411 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15067776 0.77 CCR1 (0.50) CCR1RAB9ACCR5MAPTMDM2
SCHEMBL22250698 0.77 CCR1 (0.50) CCR1RAB9ACCR5MAPTL3MBTL1
SCHEMBL10698909 0.74 KDM4E (0.48) CCR1RAB9ACCR5MAPTL3MBTL1
SCHEMBL20666234 0.74 NR4A2 (0.41) MAPTL3MBTL1NR4A2KDM4EGAA
SCHEMBL16743118 0.74 CCR1 (0.50) CCR1RAB9ACCR5MAPTL3MBTL1
SCHEMBL21787615 0.73 CCR1 (0.45) CCR1RAB9ACCR5MAPTL3MBTL1
SCHEMBL20049296 0.72 ALDH1A1 (0.33) RAB9AMAPTNR4A2PDE2APDE10A
SCHEMBL20675602 0.70 CCR1 (0.46) CCR1CCR5KDM4ECYP1A2
SCHEMBL25410328 0.69 TTR (0.44) CCR1RAB9ACCR5MAPTKDM4E
SCHEMBL31610926 0.69 TTR (0.44) CCR1RAB9ACCR5MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220220111-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF NUVATION BIO OPERATING COMPANY INC (US) 2022-07-14 US disclosed
US-10793561-B2 1,8-naphthyridinone compounds and uses thereof NUVATION BIO INC. (US) 2020-10-06 US disclosed
US-20190023702-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220111-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF NME1, ADORA2A, GPR68 CCR1 1998/4885RAB9A 1317/4885CCR5 1436/4885
US-10793561-B2 1,8-naphthyridinone compounds and uses thereof NME1, ADORA2A, GPR68 CCR1 1998/4885RAB9A 1317/4885CCR5 1436/4885
US-20190023702-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF NME1, ADORA2A, GPR68 CCR1 1998/4885RAB9A 1317/4885CCR5 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.